Role of cetrorelix in the prevention and treatment of ovarian hyperstimulation syndrome: A prospective case control study

---

Original Article

Author Details : Anita Inani*

Volume : 10, Issue : 4, Year : 2023

Article Page : 132-136

https://doi.org/10.18231/j.jchm.2023.030

Suggest article by email

Get Permission

---

Abstract

Background: Because of its terrible effects, ovarian hyperstimulation syndrome (OHSS) has long piqued the interest of medical professionals. Since the syndrome is an iatrogenic condition brought on by elective ovarian stimulation in the pursuit of pregnancy, its complete prevention is imperative. The gonadotropin releasing hormone (GnRH) antagonist Cetrorelix has been shown in some studies to be beneficial in the prevention of OHSS as well as an effective treatment for the condition. Therefore, we created a study at a hospital to find out how Cetrorelix works to prevent and treat OHSS in patients undergoing long and short protocols for those undergoing embryo transfer and in-vitro fertilization (IVF–ET) who are susceptible to the illness.
Materials and Methods: The study includes 102 patients undergoing COS for IVF in total. To stimulate each case, a long and a short protocol were employed. Depending on whether a GnRH antagonist was administered following ovum pick-up (OPU), the patients were split into two groups: the control group (n = 51) and the Cetrorelix (antagonist) group (n = 51). Beginning on the day of ovum pickup, the study group received five days' worth of Cetrorelix 0.25 mg.
Results: While the antagonist group had a significantly higher moderate OHSS incidence (p=0.01), the incidence between mild and severe OHSS was considerably reduced(p<0> Conclusion: OHSS can be prevented and treated effectively by administering the GnRH antagonist Cetrorelix to patients undergoing either a long- or short-term protocol during the early luteal phase.

Keywords: Ovarian hyperstimulation syndrome, Gonadotropin-releasing hormone antagonist, Ceterorelix

How to cite : Inani A, Role of cetrorelix in the prevention and treatment of ovarian hyperstimulation syndrome: A prospective case control study. J Community Health Manag 2023;10(4):132-136

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.